Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
Janus Living, Inc. reports developments as a pure-play senior housing real estate investment trust focused on senior housing communities across the United States. Company news centers on quarterly operating results, same-store revenue, occupancy and RevPOR trends, dividend declarations, liquidity actions, acquisition and investment activity, and the use of proceeds from its completed initial public offering.
Recurring updates also address Janus Living’s Class A-1 common stock trading on the New York Stock Exchange, its external management relationship with Healthpeak Properties, and capital resources such as unsecured revolving credit and term loan facilities used for general corporate purposes and portfolio growth.
JanOne Inc. (Nasdaq: JAN) has officially changed the internal name of its drug candidate from TV1001SR to JAN101. This candidate is set to enter Phase 2b clinical trials targeting Peripheral Artery Disease (PAD), which affects over 8.5 million Americans. The name change aligns with the company's new naming conventions for its clinical pipeline. CEO Tony Isaac emphasized the importance of this rebranding for clinical clarity. JanOne continues to advance its mission to provide non-addictive pain treatments while reviewing its legacy businesses.
JanOne Inc. (NASDAQ:JAN) has enhanced its scientific advisory board with the appointments of Dr. John Cooke and Dr. Alan Kaye. Dr. Cooke brings over 30 years of vascular expertise, crucial for advancing treatments for Peripheral Artery Disease (PAD), affecting over 8.5 million Americans. Dr. Kaye, an expert in pain management, will focus on non-addictive pain solutions. CEO Tony Isaac emphasized the significance of their expertise in expanding JanOne's clinical pipeline as the company prepares for phase 2b trials for its lead candidate.
JanOne Inc. (NASDAQ: JAN) has received FDA confirmation for the transfer of investigational new drug (IND) sponsorship for its sodium nitrite tablets, now named TV1001SR, from Soin Neuroscience. This drug targets peripheral artery disease (PAD) and other vascular conditions, addressing a significant unmet need, as over 8.5 million Americans suffer from PAD. Manufacturing is in progress, with Phase 2b trials anticipated to start this year. Sodium nitrite has shown promise in treating vascular issues with minimal adverse effects, enhancing JanOne's clinical research prospects.
JanOne Inc. (NASDAQ: JAN) has expanded its scientific advisory board by adding Dr. Rakesh Patel and Dr. Timothy Ness from the University of Alabama at Birmingham. Dr. Patel specializes in molecular and cellular pathology, focusing on inflammation and nitric oxide research. Dr. Ness, an expert in pain mechanisms, has an extensive background in pain treatment and clinical trials. Their expertise aims to enhance JanOne's development of non-addictive pain treatments, particularly for peripheral artery disease, which affects over 8.5 million Americans.
JanOne Inc. (NASDAQ:JAN) announced the addition of Dr. Edgar Ross to its scientific advisory board on June 30, 2020. Dr. Ross, a distinguished pain management specialist and director at Brigham and Women's Hospital, brings over 40 years of experience and has published extensively in the field. His expertise aims to enhance JanOne's mission to develop non-addictive pain relief solutions. CEO Tony Isaac expressed confidence in Dr. Ross’s contributions towards innovative alternatives to opioids as the company advances its phase 2b trials for treatments related to peripheral artery disease.
JanOne Inc. (NASDAQ: JAN) has appointed Dr. Douglas Flanagan as its chief formulation advisor, enhancing its biopharma team. Dr. Flanagan will work with manufacturing partner CoreRX on TV1001SR, aimed at treating Peripheral Artery Disease (PAD), which is set to enter phase 2 trials soon. With over 40 years of experience and expertise from working with leading pharmaceutical companies, Dr. Flanagan is expected to facilitate the development of additional pain treatment candidates. The company is committed to non-addictive pain relief solutions while continuing its legacy operations.
JanOne (Nasdaq:JAN) has initiated a strategic alternatives process for its legacy businesses to enhance shareholder value. The review, supported by financial and legal advisors, will explore various options including acquisitions, joint ventures, and capital raises. CEO Tony Isaac emphasized the focus on advancing their clinical candidate, TV1001SR, aimed at treating Peripheral Artery Disease (PAD). With no guarantees on the outcomes of this strategic review, the company will not provide updates until necessary. JanOne remains committed to addressing severe pain through innovative, non-addictive treatments.